


CLAIMS

1. Use of at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of
 5 formula (I) below:




in which:

10

- R₂ and R₃, which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:

15




also possibly forming the Pro (proline) residue, and

- 20
- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester;

for the manufacture of a medicinal product capable of selectively inhibiting the C-terminal site of angiotensin I converting enzyme.

- 5 2. Use of a phosphinic pseudopeptide derivative corresponding to formula (II) below:




- 10 in which:

- R₁ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

15

- R₂ and R₃, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



20

also possibly forming the Pro residue,

- R₄ represents a hydrogen atom or a pharmacologically acceptable counterion, and
- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester;

for the manufacture of a medicinal product capable of selectively inhibiting the C-terminal site of angiotensin I converting enzyme.


3. Use according to Claim 2, in which R₁ represents a protecting group for an amine function chosen from acetyl and benzyloxycarbonyl groups.

15

4. Use according to any one of Claims 1 to 3, in which R₂ represents the benzyl, methyl or phenylethyl group.


20 5. Use according to any one of Claims 1 to 4, in which R₃ represents the side chain of alanine, arginine or tryptophan.

25 6. Use according to any one of Claims 1 to 4, in which the sequence -NH-CH(R₃)-CO- forms the Pro residue:




7. Use according to any one of Claims 1 to 6, in which R₄ and/or R₅ represent(s) a hydrogen atom.

8. Use according to Claim 2, in which the phosphinic
5 pseudopeptide derivative corresponds to the formula:



(pseudo-peptide G)

9. Phosphinic pseudopeptide derivative comprising the
10 amino acid sequence of formula (I) below:




in which:


15

- R₂ represents the side chain of a natural or unnatural amino acid,

- the sequence:




5 forms the Pro residue:



- R₄ represents a hydrogen atom or a pharmacologically acceptable counterion, and
- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester.

15

10. Phosphinic pseudopeptide derivative corresponding to formula (II) below:



20 in which:


- R₁ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

5

- R₂ represents the side chain of a natural or unnatural amino acid,


- the sequence:

10



forms the Pro residue:


15



- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group capable of forming an *in vivo* hydrolysable phosphinic ester.

20

11. Phosphinic pseudopeptide derivative of formula:




(pseudo-peptide G)

12. Pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative according to any
5 one of Claims 9 to 11.


13. Pharmaceutical composition, in which the phosphinic pseudopeptide derivative corresponds to the formula:

10



(pseudo-peptide G)

14. Process for preparing a pseudopeptide of formula:




5 in which:

- R₁ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

10

- R₂ and R₃, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:


15




also possibly forming the Pro residue, and

- R₄ and R₅ represent a hydrogen atom;
- 20 which comprises the following steps:


1) reacting a compound of formula (III):



5 in which R_1 and R_2 are as defined above, with the compound of formula (IV):




10 in which Ac represents the acetyl group and Et represents the ethyl group, to obtain the compound of formula (V):




15


2) converting compound (V) into compound (VI) by reacting compound (V) with sodium borohydride:



3) protecting the hydroxyl group of compound (VI) with
 5 a protecting group R_5 , for example the adamantly
 group Ad, to give the compound of formula (VII):



10 4) saponifying compound (VII) to give the compound of
 formula (VIII):



15 5) coupling the compound of formula (VIII) with the
 amino acid of formula (IX) or (X):



(IX)

or




(X)

in which R_3 is as defined above, and

5 6) removing the protecting group Ad.

15. Process according to Claim 14, in which the peptide coupling step 5) is performed via solid-phase peptide synthesis using as solid phase a resin
10 substituted with the amino acid of formula (IX) or (X).

16. Process for preparing a pseudopeptide of formula:




15

in which:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected
20 with a protecting group for an amine function,

- R₂ and R₃, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:

5




also possibly forming the Pro residue,

- R₄ represents a hydrogen atom, and
10
- R₅ represents a group capable of forming an *in vivo* hydrolysable phosphinic ester;

15 in which the phosphinic function of the pseudopeptide obtained via the process of Claim 14 or 15 is esterified by coupling with an alcohol of formula R₅OH or by reaction with a halide of formula R₅X in which X represents a halogen atom.

20 17. Compound of formula (VIII):



in which:

- R₁ represents a protecting group for an amine function or an amino acid or a peptide protected
5 with an amine function, and
- R₂ represents the side chain of a natural or unnatural amino acid.